Sharekhan has given Buy recommendation for Aurobindo Pharma with a target price of Rs. 1100 in its research report issued on Feb 11, 2021

Sharekhan’s research report on Aurobindo Pharma

Q3FY2021 revenues, operating profits and PAT slightly lagged estimates; adjusting for one-off gains, PAT stood at Rs. 836 crore, up 18.5% y-o-y but missed estimates. Expected traction in injectable, strong growth outlook for US and Europe geographies would be the key growth drivers, while the areas of Vaccine and API would fuel the growth over the long term. Focus on building and developing a strong portfolio of specialty products (biosimilars, oncology, inhalers, transdermal patches, etc) would be key growth drivers.


We retain our Buy recommendation on Aurobindo Pharma Limited (Aurobindo) with a revised PT of Rs. 1,100.